Compare Ascendis Pharma A/S (ASND) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Hyatt Hotels Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Hyatt Hotels Corporation trades at $190.5 (market cap $18.00B). The key difference: Ascendis Pharma A/S and Hyatt Hotels Corporation are close in size by market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | H | |
|---|---|---|
Market Cap | $17.74B | $18.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $202.09 |
52-Week Low | $163.32 | $135.01 |
Enterprise Value | $18.11B | $21.84B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Hyatt Hotels Corp (H) trades at $191.14, up 0.63% on the day, with a bearish technical signal but mixed earnings performance. Recent quarters show beats on EPS estimates, though net income margin remains negative at -0.48%. The company announced expansion plans, including a new Hyatt Regency in Tucson, amid stable revenue around $7.1B. Cash flow trends indicate operational challenges, with net cash flow turning negative in 2025.
Outlook is cautious with analyst consensus tilted toward Hold (52.08%). Upside exists if operational efficiency improves and travel demand sustains, but risks include high debt levels and profitability pressures. The stock trades near the consensus price target of $197.30, suggesting limited near-term upside without fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
